Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Atrophic vaginitis affects the majority of post-menopausal women. It is characterized by
dryness and inflammation of the vagina, with thinning of the vaginal tissues. Atrophic
vaginitis is caused by the decreased effect of estrogens post menopause. Traditionally, local
estrogens have been used to treat atrophic vaginitis
Studies have shown that there are progesterone receptors in vaginal tissues. The use of
progesterone to treat atrophic vaginitis has not yet been studied. However, its use has been
studied in other populations including as a fertility medication in pregnant women.
There is a significant group of women who cannot use, choose not to use, or do not respond to
estrogenic therapies. The goal of this study is to evaluate the efficacy of vaginal
progesterone in the treatment of urogenital atrophy, compared to placebo. This study is a
randomized, double-blind, placebo controlled trial. The ultimate goal is to expand the
treatment options for patients with symptoms of vaginal atrophy.